Universal access to drug susceptibility testing for newly diagnosed tuberculosis patients is recommended. Access to culture-based diagnostics remains limited, and targeted molecular assays are vulnerable to emerging resistance mutations.
Journal article
American Society for Microbiology
2023-03-23T00:00:00+00:00
61